EU Panel Backs Olaparib Approval for Frontline Maintenance in Ovarian Cancer

April 29, 2019 – The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of olaparib as a frontline maintenance treatment for patients with BRCA-mutant advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response (PR) following first-line platinum-based chemotherapy. The positive opinion is based on findings from the phase III SOLO-1 trial, in which olaparib … (leggi tutto)